The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20081127
The Journal of Experimental Medicine, Vol. 206, No. 4, 923-936
The Rockefeller University Press, 0022-1007 $30.00
© Price et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 6171K)
Right arrow PDF+supp data (11041K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, D. A.
Right arrow Articles by Douek, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, D. A.
Right arrow Articles by Douek, D. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection

David A. Price1,4, Tedi E. Asher1, Nancy A. Wilson5, Martha C. Nason2, Jason M. Brenchley1,3, Ian S. Metzler1, Vanessa Venturi6, Emma Gostick4, Pratip K. Chattopadhyay1, Mario Roederer1, Miles P. Davenport6, David I. Watkins5, and Daniel C. Douek1

1 Vaccine Research Center, 2 Biostatistics Research Branch, and 3 Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
4 Department of Medical Biochemistry and Immunology, Cardiff University School of Medicine, Cardiff CF14 4XN, Wales, UK
5 Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI 53711
6 Centre for Vascular Research, University of New South Wales, Kensington 2052, Sydney, Australia

CORRESPONDENCE David A. Price: dprice1{at}mail.nih.gov OR Daniel C. Douek: ddouek{at}mail.nih.gov

Despite the pressing need for an AIDS vaccine, the determinants of protective immunity to HIV remain concealed within the complexity of adaptive immune responses. We dissected immunodominant virus-specific CD8+ T cell populations in Mamu-A*01+ rhesus macaques with primary SIV infection to elucidate the hallmarks of effective immunity at the level of individual constituent clonotypes, which were identified according to the expression of distinct T cell receptors (TCRs). The number of public clonotypes, defined as those that expressed identical TCR β-chain amino acid sequences and recurred in multiple individuals, contained within the acute phase CD8+ T cell population specific for the biologically constrained Gag CM9 (CTPYDINQM; residues 181–189) epitope correlated negatively with the virus load set point. This independent molecular signature of protection was confirmed in a prospective vaccine trial, in which clonotype engagement was governed by the nature of the antigen rather than the context of exposure and public clonotype usage was associated with enhanced recognition of epitope variants. Thus, the pattern of antigen-specific clonotype recruitment within a protective CD8+ T cell population is a prognostic indicator of vaccine efficacy and biological outcome in an AIDS virus infection.


Abbreviations used: Ad5, adenovirus serotype 5; i.m., intramuscularly; PI, postinfection; PV, postvaccination; pVL, plasma virus load.

© 2009 The Rockefeller University Press
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS